DK0709097T3 - Anti-Fas antistof mod reumatiske sygdomme - Google Patents

Anti-Fas antistof mod reumatiske sygdomme

Info

Publication number
DK0709097T3
DK0709097T3 DK95115210T DK95115210T DK0709097T3 DK 0709097 T3 DK0709097 T3 DK 0709097T3 DK 95115210 T DK95115210 T DK 95115210T DK 95115210 T DK95115210 T DK 95115210T DK 0709097 T3 DK0709097 T3 DK 0709097T3
Authority
DK
Denmark
Prior art keywords
fas
monoclonal antibody
antibody against
rheumatic diseases
fas antibody
Prior art date
Application number
DK95115210T
Other languages
English (en)
Inventor
Kusiki Nishioka
Shin Yoneyama
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK0709097T3 publication Critical patent/DK0709097T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK95115210T 1994-09-27 1995-09-27 Anti-Fas antistof mod reumatiske sygdomme DK0709097T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP27013494 1994-09-27

Publications (1)

Publication Number Publication Date
DK0709097T3 true DK0709097T3 (da) 2003-02-24

Family

ID=17482032

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95115210T DK0709097T3 (da) 1994-09-27 1995-09-27 Anti-Fas antistof mod reumatiske sygdomme

Country Status (9)

Country Link
US (1) US6086877A (da)
EP (1) EP0709097B1 (da)
KR (1) KR100371000B1 (da)
AT (1) ATE226447T1 (da)
CA (1) CA2158822C (da)
DE (1) DE69528624T2 (da)
DK (1) DK0709097T3 (da)
ES (1) ES2182860T3 (da)
PT (1) PT709097E (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830469A (en) * 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof
AU736287B2 (en) * 1997-03-21 2001-07-26 Sankyo Company Limited Humanized anti-human Fas antibody
WO1999065935A2 (en) 1998-06-18 1999-12-23 Karolinska Innovations Ab Fas peptides and antibodies for modulating apoptosis
KR20020008197A (ko) * 1999-05-24 2002-01-29 가와무라 요시부미 항-Ｆａｓ 항체를 함유하는 의약 조성물
US6787136B1 (en) 1999-09-03 2004-09-07 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
EP1335021A4 (en) 2000-10-24 2004-09-22 Shunichi Shiozawa GENOMS INVOLVED IN RHEUMATOID ARTHRITIS, METHOD FOR DIAGNOSIS THEREOF, METHOD FOR EVALUATING THE POSSIBILITY OF AN OUTBREAK THEREOF, DIAGNOSTIC KIT FOR DETECTING THESE GENES, THERAPEUTIC METHOD AND MEDICINE FOR ARTHRUME
US20060104951A1 (en) * 2004-11-16 2006-05-18 Mountz John D Akt and regulation of RA synovial fibroblast apoptosis
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US10071143B1 (en) 2007-05-03 2018-09-11 The Research Foundation For The State University Of New York Methods for non-surgical treatment of carpal tunnel syndrome
CA2732715C (en) * 2008-08-01 2015-04-07 Kusuki Nishioka Treatment agent or preventative agent for osteoarthritis
CN102821786B (zh) * 2010-01-29 2016-01-13 阿克西斯股份有限公司 含有骨关节炎治疗剂的注射液
AU2011210465A1 (en) * 2010-01-29 2012-08-23 Axis Inc. Pharmaceutical composition for treatment or prevention of osteoarthritis, and method of production therefor
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
EP4772625A2 (en) 2012-01-12 2026-07-08 Endo Biologics Limited Clostridium histolyticum enzyme
US9636385B2 (en) 2012-10-24 2017-05-02 The Research Foundation For The State University Of New York Use of collagenase to treat glaucoma
US11097005B2 (en) 2014-12-15 2021-08-24 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity
DK3589204T3 (da) 2017-03-01 2025-06-30 Endo Operations Ltd Apparat og fremgangsmåde til vurdering og behandling af cellulitis
KR20250171475A (ko) 2017-03-28 2025-12-08 엔도 오퍼레이션즈 리미티드 개선된 콜라게나제 생성 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201712A (ja) * 1982-05-18 1983-11-24 Green Cross Corp:The 脂肪乳剤
JPS6051105A (ja) * 1983-08-30 1985-03-22 Green Cross Corp:The プロスタグランジン脂肪乳剤
JPH02237935A (ja) * 1989-03-10 1990-09-20 Bio Kagaku Kenkyusho:Kk エイズ処置剤
WO1991010448A1 (en) * 1990-01-19 1991-07-25 German Cancer Research Center A cell surface antigen associated with cellular apoptosis
CA2067031C (en) * 1991-04-26 2003-02-18 Shigekazu Nagata Dna coding for human cell surface antigen
CA2112473A1 (en) * 1991-07-05 1993-01-21 Patricia A. Bacha Epidermal growth factor receptor targeted molecules for treatment of inflammatory arthritis
CA2121148A1 (en) * 1992-08-19 1994-03-03 Otsuka Pharmaceutical Co., Ltd. Apoptosis regulator
US5830469A (en) * 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof
NZ275711A (en) * 1993-10-14 1998-03-25 Immunex Corp Monoclonal antibodies and binding proteins which bind to human fas antigen (nerve growth factor/tumour necrosis factor receptor type)

Also Published As

Publication number Publication date
EP0709097A1 (en) 1996-05-01
PT709097E (pt) 2003-03-31
DE69528624D1 (de) 2002-11-28
US6086877A (en) 2000-07-11
DE69528624T2 (de) 2003-06-26
EP0709097B1 (en) 2002-10-23
CA2158822C (en) 2008-12-23
ES2182860T3 (es) 2003-03-16
KR960010024A (ko) 1996-04-20
CA2158822A1 (en) 1996-03-28
KR100371000B1 (ko) 2003-07-12
ATE226447T1 (de) 2002-11-15

Similar Documents

Publication Publication Date Title
PT709097E (pt) Anticorpo anti-fas para a doenca reumatica
Verneuil et al. Interstitial granulomatous dermatitis with cutaneous cords and arthritis: a disorder associated with autoantibodies
CY1122391T1 (el) Pan-kir2dl nk-υποδοχεα αντισωματα και χρηση αυτων σε διαγνωστικη και θεραπεια
CY1111193T1 (el) Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους
CY2007001I2 (el) Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη
TW376320B (en) Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
BR9913645A (pt) Terapias combinadas para linfomas de células b compreendendo a administração de anticorpo anti-cd20
WO1994011026A3 (en) Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
MY111518A (en) Absorbent article having enhanced wicking capability
DE69400799D1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DK0914144T3 (da) Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
NO882406D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive urinstoff- og karbamat-forbindelser.
SE9503751D0 (sv) Dambinda
EP1706423B8 (en) Therapeutic and diagnostic anti-hsp 70 antibodies
DE68920624D1 (de) Menschlicher monoklonaler Antikörper, Hybridoma, das ihn herstellt, und pharmazeutisches Mittel.
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
DE60141297D1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
ES2167385T3 (es) Medicamentos de accion antihiperglicemica.
EE9900010A (et) T-BAM (CD40L) tehnoloogia terapeutilised rakendused silelihasrakkudega seotud haiguste ravimiseks
SE8804136L (sv) Absorberande engaangsartikel
EA199600040A1 (ru) Устройство для диагностики и адаптивной терапии
PT859613E (pt) Utilizacao de flupirtina para a profilaxia e o tratamento de doencas associadas a uma alteracao do sistema celular hematopoietico
NZ284914A (en) use of anti-arthritogenic peptide antibodies, nonadsorbable antibiotic or benign bacteria to treat rheumatoid arthritis by enteral administration
DK392288A (da) Human monoklonale antistoffer samt profylaktiske og terapeutiske midler mod infrektioese sygdomme, der indeholder samme som aktiv bestanddel
Wakabayashi et al. Long-term maintenance of golimumab effectiveness for injection spacing in rheumatoid arthritis patients with low disease activity who previously received other TNF inhibitors: minimum 2-year data from an observational study